Helaina Raises $45 Million in Series B Funding to Accelerate the Commercialization of Human Bioactive Proteins Starting with effera™ Human Lactoferrin
September 25, 2024 09:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Helaina, the biotechnology company transforming nutrition with human equivalent bioactive proteins, announced today it has raised $45 million in Series B funding, bringing the company’s…
